Promising New Treatment for Alzheimer’s Disease Licensed By Sanomune Inc.

Published: Mar 04, 2009

BLOOMINGTON, Minn.--(BUSINESS WIRE)--A Canadian bio-technology company, Sanomune Inc., licensed a new treatment method that helps drugs to reach the brain unlike any other treatment for neurological diseases. The treatment method, developed by HealthPartners Research Foundation, is a new therapeutic technology offering hope to the 5.2 million people in the United States living with Alzheimer’s disease and other neurological diseases.

Back to news